About AveXis (NASDAQ:AVXS)
AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXS
CUSIPN/A
Phone847-572-8280
Debt
Debt-to-Equity RatioN/A
Current Ratio5.70%
Quick Ratio5.70%
Price-To-Earnings
Trailing P/E Ratio-29.19
Forward P/E Ratio-27.85
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$10.37 per share
Price / Book20.49
Profitability
EPS (Most Recent Fiscal Year)($7.28)
Net Income$-218,050,000.00
Net MarginsN/A
Return on Equity-62.30%
Return on Assets-56.63%
Miscellaneous
Employees219
Outstanding Shares36,820,000
AveXis (NASDAQ:AVXS) Frequently Asked Questions
What is AveXis' stock symbol?
AveXis trades on the NASDAQ under the ticker symbol "AVXS."
How were AveXis' earnings last quarter?
AveXis (NASDAQ:AVXS) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.55) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.64) by $0.91. View AveXis' Earnings History.
When is AveXis' next earnings date?
What price target have analysts set for AVXS?
19 brokers have issued 12-month price objectives for AveXis' shares. Their predictions range from $52.00 to $171.00. On average, they expect AveXis' stock price to reach $124.5263 in the next twelve months. View Analyst Ratings for AveXis.
What are Wall Street analysts saying about AveXis stock?
Here are some recent quotes from research analysts about AveXis stock:
- 1. William Blair analysts commented, "We believe that other companies may begin to follow suit and see this as a positive for other AAV companies, most notably in our coverage, Spark (ONCE $62.06; Outperform) and Audentes (BOLD $28.11; Outperform)." (4/9/2018)
- 2. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (3/20/2018)
- 3. Mizuho analysts commented, "We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1." (2/12/2018)
- 4. Chardan Capital analysts commented, "We would encourage buying on any AVXS weakness today, on the potential that the market may have understandably misunderstood what could be an atypical but stepped up process in terms of filing timelines for AVXS-101 in SMA type 1. Our take: Our base case (see our 15 June 2017 note) of a filing after pivotal STR1VE (NCT03306277) phase III data seems to have been improved upon. There are reasons to believe AveXis could file AVXS-101 by 3Q18, with a blue skies" scenario involving AVXS-101 approval by end-2018 or early-2019. We note AveXis’ appropriately non-promotional commentary when executing its duties in communicating status of important regulatory matters to the market." (1/5/2018)
Who are some of AveXis' key competitors?
Some companies that are related to AveXis include Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), China Biologic Products (CBPO), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN) and Acceleron Pharma (XLRN).
Who are AveXis' key executives?
AveXis' management team includes the folowing people:
- Mr. Sean P. Nolan, Chief Exec. Officer, Pres and Director (Age 50)
- Dr. Sukumar Nagendran M.D., Chief Medical Officer and Sr. VP (Age 51)
- Mr. Phillip B. Donenberg CPA, Sr. VP, CFO & Principal Accounting Officer (Age 57)
- Mr. Brian K. Kaspar Ph.D., Chief Scientific Officer, Director and Member of Scientific Advisory Board (Age 44)
- Mr. Michael B. Johannesen, Chief Compliance Officer, Sr. VP and Gen. Counsel (Age 52)
When did AveXis IPO?
(AVXS) raised $86 million in an IPO on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.
Has AveXis been receiving favorable news coverage?
News headlines about AVXS stock have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AveXis earned a news impact score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 46.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are AveXis' major shareholders?
AveXis' stock is owned by a number of of institutional and retail investors. Top institutional investors include ADAGE CAPITAL PARTNERS GP, L.L.C. (6.04%). Company insiders that own AveXis stock include Andrew F Knudten, Brian K Kaspar, James J Litalien, Paul B Manning, Sean P Nolan and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.
How do I buy shares of AveXis?
Shares of AVXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AveXis' stock price today?
One share of AVXS stock can currently be purchased for approximately $212.48.
How big of a company is AveXis?
AveXis has a market capitalization of $7.73 billion. The company earns $-218,050,000.00 in net income (profit) each year or ($7.28) on an earnings per share basis. AveXis employs 219 workers across the globe.
How can I contact AveXis?
AveXis' mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company can be reached via phone at 847-572-8280 or via email at [email protected]
MarketBeat Community Rating for AveXis (AVXS)
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe AVXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
AveXis (NASDAQ:AVXS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for AveXis in the last 12 months. Their average twelve-month price target is $124.5263, suggesting that the stock has a possible downside of 41.39%. The high price target for AVXS is $171.00 and the low price target for AVXS is $52.00. There are currently 1 sell rating, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.26 | 2.68 | 2.67 | 2.59 |
| Ratings Breakdown: | 1 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
2 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $124.5263 | $124.5263 | $114.00 | $107.5294 |
| Price Target Upside: | 41.39% downside | 5.20% downside | 8.71% upside | 6.46% upside |
AveXis (NASDAQ:AVXS) Consensus Price Target History
AveXis (NASDAQ:AVXS) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
AveXis (NASDAQ:AVXS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AveXis (NASDAQ AVXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 82.28%
AveXis (NASDAQ AVXS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Brian K Kaspar | Insider | Sell | 15,000 | $119.50 | $1,792,500.00 | 1,767,766 |  |
| 4/2/2018 | James J Litalien | VP | Sell | 5,000 | $119.44 | $597,200.00 | 8,800 | |
| 3/7/2018 | Sean P Nolan | CEO | Sell | 10,000 | $129.47 | $1,294,700.00 | 10,000 | |
| 3/1/2018 | Brian K Kaspar | Insider | Sell | 15,000 | $126.15 | $1,892,250.00 | | |
| 3/1/2018 | Sukumar Nagendran | VP | Sell | 1,780 | $126.19 | $224,618.20 | | |
| 2/1/2018 | Andrew F Knudten | VP | Sell | 2,000 | $118.13 | $236,260.00 | 7,000 | |
| 2/1/2018 | Brian K Kaspar | Insider | Sell | 15,000 | $118.07 | $1,771,050.00 | 1,792,147 | |
| 1/16/2018 | James J Litalien | VP | Sell | 5,000 | $106.52 | $532,600.00 | | |
| 1/2/2018 | Brian K Kaspar | Insider | Sell | 15,000 | $109.75 | $1,646,250.00 | 1,808,386 | |
| 1/2/2018 | Sukumar Nagendran | VP | Sell | 1,780 | $109.72 | $195,301.60 | 1,780 | |
| 12/4/2017 | Andrew F Knudten | VP | Sell | 2,000 | $94.48 | $188,960.00 | 7,000 | |
| 12/1/2017 | Brian K Kaspar | Insider | Sell | 15,000 | $94.73 | $1,420,950.00 | 1,826,502 | |
| 12/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $94.77 | $168,690.60 | 1,780 | |
| 11/1/2017 | Brian K Kaspar | Insider | Sell | 15,000 | $101.23 | $1,518,450.00 | 1,841,019 | |
| 11/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $101.26 | $180,242.80 | 1,780 | |
| 10/9/2017 | Brian K Kaspar | Insider | Sell | 15,000 | $101.46 | $1,521,900.00 | | |
| 10/2/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $97.25 | $173,105.00 | 1,780 | |
| 9/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $93.25 | $165,985.00 | 1,780 | |
| 8/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $91.52 | $162,905.60 | 1,780 | |
| 7/3/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $81.88 | $145,746.40 | 1,780 | |
| 6/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $70.91 | $126,219.80 | 1,780 | |
| 5/1/2017 | Sukumar Nagendran | VP | Sell | 1,780 | $81.39 | $144,874.20 | 1,780 | |
| 4/3/2017 | Sukumar Nagendran | VP | Sell | 1,781 | $76.13 | $135,587.53 | 1,781 | |
| 9/13/2016 | Paul B Manning | Insider | Sell | 289,855 | $34.50 | $9,999,997.50 | | |
| 2/17/2016 | Bong Y Koh | Director | Buy | 100,000 | $20.00 | $2,000,000.00 | | |
| 2/17/2016 | James E Flynn | Insider | Buy | 750,317 | $19.47 | $14,608,671.99 | | |
(Data available from 1/1/2013 forward)
AveXis (NASDAQ AVXS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | AveXis (AVXS) Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1
www.streetinsider.com - April 25 at 4:27 PM |
 | Late-stage study underway for AVXS-101 in pre-symptomatic spinal muscular atrophy
seekingalpha.com - April 25 at 4:27 PM |
 | BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3
www.reuters.com - April 25 at 9:51 AM |
 | AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
finance.yahoo.com - April 25 at 9:51 AM |
| AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
finance.yahoo.com - April 25 at 9:51 AM |
| AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
finance.yahoo.com - April 24 at 4:28 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of AveXis, Inc. to Novartis for $218 Per Share is Fair to Shareholders – AVXS
finance.yahoo.com - April 23 at 4:15 PM |
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of AveXis, Inc. Buyout
finance.yahoo.com - April 23 at 4:15 PM |
| REGENXBIO: An Underappreciated Leader In Gene Editing
seekingalpha.com - April 21 at 9:32 AM |
 | -$1.95 Earnings Per Share Expected for AveXis (AVXS) This Quarter
www.americanbankingnews.com - April 21 at 3:14 AM |
| A tale of two deals—ahead of earnings, Biogen move perplexes
finance.yahoo.com - April 20 at 4:19 PM |
| Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - April 20 at 9:55 AM |
 | AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
globenewswire.com - April 19 at 9:44 AM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
finance.yahoo.com - April 19 at 9:44 AM |
| AveXis Target of Unusually Large Options Trading (AVXS)
www.americanbankingnews.com - April 19 at 8:32 AM |
| AveXis (AVXS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 11:28 AM |
| AveXis (AVXS) Cut to Hold at Jefferies Group
www.americanbankingnews.com - April 18 at 9:00 AM |
| Nationwide Children's Hospital reports new highs in tech licensing deals and income from 2017
finance.yahoo.com - April 17 at 4:39 PM |
 | Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts
www.nasdaq.com - April 17 at 10:01 AM |
| AveXis (AVXS) Earns Outperform Rating from Analysts at Sanford C. Bernstein
www.americanbankingnews.com - April 15 at 4:30 PM |
 | AveXis Sale: An $8.7 Billion Endorsement for Gene Therapy
www.barrons.com - April 14 at 9:52 AM |
| AveXis (AVXS) Coverage Initiated at Morgan Stanley
www.americanbankingnews.com - April 13 at 6:39 PM |
| Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?
finance.yahoo.com - April 13 at 4:17 PM |
| Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
finance.yahoo.com - April 13 at 4:17 PM |
| Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
finance.yahoo.com - April 13 at 4:17 PM |
| Pharma M&A Active This Week: 4 Potential Buyout Targets
finance.yahoo.com - April 13 at 4:17 PM |
| Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
finance.yahoo.com - April 13 at 4:17 PM |
| AveXis (AVXS) Lowered to Neutral at Chardan Capital
www.americanbankingnews.com - April 13 at 10:37 AM |
| Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?
finance.yahoo.com - April 13 at 10:10 AM |
| AveXis' (AVXS) "Overweight" Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - April 12 at 2:52 PM |
| AveXis (AVXS) Stock Rating Lowered by Barclays
www.americanbankingnews.com - April 12 at 10:45 AM |
 | WEISSLAW LLP Investigates AveXis Inc. Acquisition
www.bizjournals.com - April 12 at 10:39 AM |
| GSK slims portfolio with sale of rare disease gene therapy drugs
finance.yahoo.com - April 12 at 10:39 AM |
| AveXis (AVXS) Rating Lowered to Hold at UBS
www.americanbankingnews.com - April 12 at 10:19 AM |
| SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of AveXis, Inc.- AVXS
finance.yahoo.com - April 11 at 10:23 AM |
| AveXis (AVXS) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - April 11 at 9:31 AM |
| Traders Purchase Large Volume of Call Options on AveXis (AVXS)
www.americanbankingnews.com - April 11 at 7:06 AM |
| Novartis' Acquisition of AveXis Takes Aim at Biogen
finance.yahoo.com - April 10 at 4:16 PM |
| Novartis' Acquisition of AveXis Takes Aim at Biogen
finance.yahoo.com - April 10 at 4:16 PM |
| How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal
finance.yahoo.com - April 10 at 4:16 PM |
| AveXis (AVXS) Downgraded by Citigroup to "Neutral"
www.americanbankingnews.com - April 10 at 1:42 PM |
 | Novartis' Acquisition of Avexis: Bad News for Biogen?
www.msn.com - April 10 at 10:08 AM |
| Why the Deal for AveXis Is a Powerful Vote for Replacement Gene Therapy
www.barrons.com - April 10 at 10:08 AM |
| AveXis (AVXS) Enters Overbought Territory
finance.yahoo.com - April 10 at 10:08 AM |
| Today’s Research Reports on Stocks to Watch: AveXis and Novartis
finance.yahoo.com - April 10 at 10:08 AM |
| AveXis (AVXS) Lifted to "Neutral" at Nomura
www.americanbankingnews.com - April 9 at 5:52 PM |
 | Novartis buys AveXis in $8.7 billion gene therapy bet
www.businessinsider.com - April 9 at 4:14 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of AveXis, Inc. to Novartis for $218 Per Share is Fair to Shareholders
finance.yahoo.com - April 9 at 4:14 PM |
| Stocks Rise on Softer U.S. Approach in China Trade War
finance.yahoo.com - April 9 at 4:14 PM |
 | Analyst: AveXis M&A Could Support Interest In Regenxbio
feeds.benzinga.com - April 9 at 1:57 PM |
AveXis (NASDAQ:AVXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AveXis (NASDAQ:AVXS) Income Statement, Balance Sheet and Cash Flow Statement
AveXis (NASDAQ AVXS) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
